The complaint alleges that Moderna used the patented fluorescent protein technology without permission during preclinical ...

BofA Securities is out with a screen of the stocks most shorted by hedge funds as a percentage of float. Strategists estimate ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...

The futures are trading flat on Wednesday after a second strong day for Wall Street, as the Dow Jones Industrial Average hit ...

Wall Street ended higher on Tuesday, as chip stocks surged on renewed AI optimism, Moderna rallied and the Dow Jones ...

Wall Street saw record highs on Tuesday driven by a rally in AI-charged chip stocks and a price boost for Moderna. The Dow ...

Wall Street saw an uplift as healthcare and tech stocks led the market, with notable gains in Moderna and chipmakers.

The real question for business leaders is not whether AI is overhyped, but how to harness its capabilities to drive ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

AI dominance, USPTO upheaval and landmark copyright rulings captured the attention of trademark professionals in 2025.

An update from Moderna ( ($MRNA) ) is now available. In a January 5, 2026 letter to shareholders, Moderna reviewed a challenging 2025 operating ...